Products
Latest Partnered Companies
.jpg){kind=logo}
Projects
Estimated Cost :
$365 million
Amgen to build new Manufacturing Facility in U.S
Amgen recently announced plans to expand its U.S.-based manufacturing footprint by building a new, final product advanced assembly and packaging plant...
Estimated Cost :
€165 Million
BD to Build New €165 Million Manufacturing Facility in Zaragoza, Spain
BD to build a €165 million high-tech manufacturing facility in the city of Zaragoza, located in the Aragon region of Spain
Estimated Cost :
-
Samsung Biologics Constructs Super Plant 4 in South Korea
Samsung Biologics plans to open the most innovative biomanufacturing facility with the addition of super plant 4. The modern super plant 4 will be loc...
Estimated Cost :
€400 million
Sanofi to invest €400 million to Create a Unique Vaccine Production Site in Singapore
Sanofi announced a €400 million investment over five years to create a unique vaccine production
Press Release
ADQ strengthens its Healthcare & Pharma portfolio with the agreed acquisition of the pharmaceutical company Acino
ADQ, one of the region's largest holding companies with a broad portfolio of large companies from all of Abu Dhabi's major and diversified economic sectors , has reached a definitive agreement to acquire Acino-based headquarters in Switzerland, a leading supplier of high-quality pharmaceuticals with a focus on high-growth markets in the Middle East,
Avista Capital Partners and Nordic Capital to sell Acino, a leader in advanced drug delivery technologies, to ADQ
Leading healthcare investors Avista Capital Partners and Nordic Capital today announced that they have entered into a definitive agreement to sell Acino ("Acino" or "the Company"), a Swiss pharmaceutical company headquartered in Zurich with a global platform that promotes affordable healthcare in key emerging markets through contract manufacturing and out-licensing. The acquirer, ADQ is one of the region's largest holding companies with a broad ...
Nouscom announces initial results from Phase 1 trial for NOUS-209, an 'off-the-shelf' neoantigen cancer vaccine, in MSI-H solid tumors
Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized cancer neoantigen vaccines, today announced initial results from the Phase 1 trial of NOUS-209, the first clinical results for the company. NOUS-209, an off-the-shelf cancer vaccine based on shared neoantigens, in combination with the anti-PD-1 checkpoint inhibitor pembrolizumab, was shown to be safe, highly immunogenic, and demonstrated promising early si ...
Theravance Biopharma, Inc. Announces Strategic Actions to Focus on Respiratory Disease Portfolio
Theravance Biopharma, Inc. today announced strategic actions to focus on leveraging its expertise in developing and commercializing respiratory therapeutics in order to maximize shareholder value. These changes follow a comprehensive scenario planning exercise led by the Board and Management with the assistance of outside advisors. In order
Events
Asia Pacific Pharmaceutics & Drug Delivery Congress 2021
SMi’s inaugural Oligonucleotide Therapeutics and Delivery
Healthcare Automation and Digitalization Congress 2021
Articles
Top 12 Analytical Lab Equipments in Pharmaceutical Industry
The analytical lab equipments or instruments are used in analytical applications in pharmaceutical, food-processing laboratories
A Complete Guide on Blister Packaging Machine
Packaging machinery is one of the vital equipment in the pharmaceutical industry, food processing, and chemical
Nanotechnology in Drug Delivery to Eyes, Skin, and Wounds Via Topical Route
One of the most favored courses for administering medications to eyes, skin, and wounds is the topical route. The principle objective for this
An Overview - Active Pharmaceutical Ingredient (API)
Active Pharmaceutical Ingredient (API) is the term used to refer to the biologically active component of a drug product
Next-Generation Biological Therapeutics Discovery & Development
Focus on drug discovery and development has shifted away from small to large, complex molecular entities
Expert Talk
Testimonials
I have read it with interest. I think it could be of interest to managers and professionals in Asia's Pharma companies as well as global companies that wish to learn more about how to do business--from R&D to marketing-in Asia.
Baoping Wang - Research Director
Novo Nordisk (China) R&D Centre
See your banner here...
.jpg)
Thank you for contacting us. One of our support staff will get in touch with you shortly.
Happy Surfing!
Regards,
Client Success Team (CRM),
